SCHEMBL3985716

SCHEMBL3985716

Cc1nn(Cc2ccc3c(c2)OCO3)c(=O)c2c(O)c3n(c12)CCN(C)C3=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.46
GAA P10253 1/20 0.41
CMA1 P23946 1/20 0.41
TSHR P16473 5/20 0.41
KDM4E B2RXH2 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
CASP1 P29466 2/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 5/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
USP2 O75604 3/20 0.38
POLB P06746 2/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16253841 0.89 PDE5A (0.46) PDE5AGAACMA1TSHRKDM4E
SCHEMBL3985002 0.86 NPBWR1 (0.35) PDE5AKMT2AMEN1LMNAPOLB
SCHEMBL3985863 0.85 PKM (0.35) GAATSHRKMT2AMAPTMEN1
SCHEMBL3981492 0.84 MAOB (0.40) GAATSHRMAPTLMNAALDH1A1
SCHEMBL3985346 0.84 PKM (0.36) KMT2AMEN1ALDH1A1HTTPOLB
SCHEMBL3992564 0.83 PDE5A (0.38) PDE5ATSHRKDM4EKMT2AMAPT
SCHEMBL1386093 0.83 LMNA (0.34) PDE5AKMT2AMAPTMEN1LMNA
SCHEMBL3983532 0.83 PKM (0.44) GAATSHRKDM4EKMT2AMAPT
SCHEMBL3985461 0.83 PDE5A (0.39) PDE5AGAAKMT2AMAPTMEN1
SCHEMBL3983972 0.81 RXFP1 (0.40) KDM4EMAPTHSD17B10ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP PDE5A 422/4885GAA 3093/4885CMA1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.